Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma: early-phase trial registry
78 of 200 indexed Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #49 of 28,707 conditions by registered trial count.
200 US clinical trials · 78 currently recruiting · #49 of 28,707 conditions by registered trial count
Glioblastoma: 200 US clinical trials tracked, 78 recruiting.
Glioblastoma is the subject of 200 registered US clinical trials on ClinicalTrials.gov, 78 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 148 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.
Enrollment posture brief
Registry condition glioblastoma
OPEN 78 | RECR 39% | LATE 15 | EARLY 148 | RANK #49 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Chronic Myeloid Leukemia (39% recruiting · 36 trials)
Glioblastoma lists 78 open slots (39% of 200 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma recruits in line with its size-band peers.
78 of 200 indexed trials (39%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioblastoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 10 of 200 trials (5%). 112 distinct sponsors appear on at least one study for this condition label.
-
Most Glioblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 200 trials that report a genuine target (sentinel values excluded). 153 of those (76.5%) plan for fewer than 100 participants.
-
Glioblastoma research is mostly interventional.
186 interventional and 14 observational studies make up this index (93% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
200 total, page 1 of 4
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Global Coalition for Adaptive Research
NCT03970447
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Jasper Gerritsen
NCT06146738
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Jasper Gerritsen
NCT06118723
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
GT Medical Technologies
NCT07195591
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NovoCure
NCT06556563
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Jasper Gerritsen
NCT06146725
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Jasper Gerritsen
NCT06283927
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Patrick Wen, MD
NCT02977780
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
Erasmus Medical Center
NCT04708171
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Ivy Brain Tumor Center
NCT06388733
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
NCT05271240
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
NCT05839379
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
NCT06273176
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Sabine Mueller, MD, PhD
NCT04732065
Key Longitudinal Associations With Risk and Glioblastoma Outcomes
Duke University
NCT06625684
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida
NCT06991101
Serial MRI Scans During Radiation Therapy
Dana-Farber Cancer Institute
NCT04188535
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Cancer Institute (NCI)
NCT06161519
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics
NCT04678648
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT05843253
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
Baptist Health South Florida
NCT05756985
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
M.D. Anderson Cancer Center
NCT04479696
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical
NCT07225621
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT04541082
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
Mayo Clinic
NCT04047264
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
Mayo Clinic
NCT05917145
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Philogen S.p.A.
NCT06336291
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
St. Joseph's Hospital and Medical Center, Phoenix
NCT06072586
Surgical Pembro +/- Olaparib w TMZ for rGBM
L. Nicolas Gonzalez Castro, MD, PhD
NCT05463848
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Northwell Health
NCT03213002
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics
NCT05879367
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
NCT03603405
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
NCT06934889
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
NCT02287428
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
Jonsson Comprehensive Cancer Center
NCT06090903
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Case Comprehensive Cancer Center
NCT07003542
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT05835687
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med
NCT05283330
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Nicholas Butowski
NCT05557292
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT06672575
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
NCT04623931
Venous Thromboembolism Prevention in Outpatients With Glioma
University of Vermont Medical Center
NCT05683808
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
Washington University School of Medicine
NCT05281731
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
NCT02800486
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Theodore S. Johnson
NCT05106296
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio
NCT06061809
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
NCT02861898
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
University of Maryland, Baltimore
NCT04699773
LITT Followed by Hypofractionated RT for Recurrent Gliomas
University of Maryland, Baltimore
NCT04181684
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Northwell Health
NCT05954858
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 61 |
| Phase 3 | 13 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma page
200 registered trials, 78 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 78 Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Glioblastoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma condition card totals 200 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.